Glivec 400 — Imatinib 400 mg, 30 pcs, Novartis

Glivec 400 — imatinib 400 mg, 30 tablets, Novartis

Product code: 522

9480₴ On order · from 10 days

Analogues

Glivec 400 Imaxen 400 Veenat 400
1
Active ingredient
Dosage form Tablets
Tablets per pack 30

Glivec 400 is the original targeted anticancer medicine by Novartis from the class of protein tyrosine kinase inhibitors. Each film-coated tablet contains 400 mg of imatinib (Glivec 400 mg Film Kaplı Tablet). Imatinib, first launched under the Glivec brand, was the first targeted therapy in hematologic oncology and transformed the outlook for chronic myeloid leukemia.

Imatinib selectively blocks the Bcr-Abl tyrosine kinase produced by a chromosomal abnormality — the Philadelphia chromosome. It inhibits proliferation and induces death of Bcr-Abl-positive leukemic cells. Imatinib also inhibits the c-Kit (CD117) and PDGFR receptor tyrosine kinases, which makes it effective in gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans and several rare blood disorders.

Turkish market pack: 30 tablets of 400 mg in a carton with a Turkish-language leaflet. Marketing authorization holder and manufacturer: Novartis Sağlık, Gıda ve Tarım Ürünleri San. ve Tic. A.Ş. (Istanbul, Turkey). Taken orally on a long-term basis, strictly as prescribed by a hematologist or oncologist.

Key features of Glivec 400:

  • ✅ Original Novartis imatinib: The very medicine on which international treatment standards for chronic myeloid leukemia and GIST were built.
  • ✅ Targeted action: Selective inhibition of the Bcr-Abl, c-Kit and PDGFR tyrosine kinases.
  • ✅ Convenient strength: One 400 mg tablet is the standard daily dose in chronic-phase CML and GIST.
  • ✅ One-month supply: 30 tablets per pack — 30 days of treatment at 400 mg a day.
  • ✅ Turkish Novartis pack: Manufactured at the Novartis plant in Istanbul (Pendik), with Turkish medicine-tracking labeling.

Glivec 400 is supplied as film-coated tablets for oral use.

Each tablet contains:

  • • Active substance: imatinib mesylate 478 mg, equivalent to 400 mg imatinib.
  • • Excipients: microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, anhydrous colloidal silica, polyethylene glycol 4000, talc.
  • • Film coating: red iron oxide (E172), yellow iron oxide (E172).

Appearance: dark yellow to brownish-orange oval tablets with bevelled edges, debossed "NVR" on one side and "SL" on the other.

Pack: 30 tablets in blisters, in a carton with a Turkish-language patient leaflet.

Pharmacodynamics:
Imatinib is a protein tyrosine kinase inhibitor. It inhibits the Bcr-Abl tyrosine kinase at the cellular level, selectively suppresses proliferation and induces apoptosis of Bcr-Abl-expressing cells, including leukemic cells in Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGFR) and stem cell factor (c-Kit, CD117), blocking growth signals in gastrointestinal stromal tumor and dermatofibrosarcoma cells.

Pharmacokinetics:

  • • Absorption: mean absolute bioavailability is about 98%. Peak plasma concentrations are reached 2–4 hours after dosing. A high-fat meal has only a minor effect on absorption.
  • • Distribution: about 95% of imatinib is bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
  • • Metabolism: in the liver, mainly by CYP3A4. The main circulating metabolite, the N-demethylated piperazine derivative, has activity similar to the parent drug.
  • • Elimination: the half-life is about 18 hours for imatinib and about 40 hours for the active metabolite. About 81% of the dose is eliminated within 7 days: 68% in feces and 13% in urine.

Glivec 400 is used in adults and children for:

  • • Chronic myeloid leukemia (CML): newly diagnosed Philadelphia chromosome-positive (Bcr-Abl) CML, and chronic phase after failure of interferon-alpha, accelerated phase or blast crisis.
  • • Ph-positive acute lymphoblastic leukemia (Ph+ ALL): newly diagnosed — combined with chemotherapy; relapsed or refractory — as monotherapy (adults).

In adults only:

  • • Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGF receptor gene rearrangements.
  • • Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.
  • • Gastrointestinal stromal tumors (GIST): Kit (CD117)-positive unresectable and/or metastatic GIST, and adjuvant treatment after resection in patients at significant risk of relapse.
  • • Dermatofibrosarcoma protuberans (DFSP): unresectable, recurrent or metastatic disease not eligible for surgery.

Treatment should be prescribed and dosed only by a physician experienced in treating hematologic malignancies. The dose depends on the diagnosis, disease phase and tolerability.

Usual starting doses in adults:

  • • CML: 400 mg or 600 mg once daily, depending on the disease phase.
  • • GIST: 400 mg once daily.
  • • Ph+ ALL: 600 mg once daily.
  • • MDS/MPD: 400 mg once daily.
  • • HES/CEL: 100 mg daily, may be increased to 400 mg if needed.
  • • DFSP: 800 mg daily — 400 mg in the morning and 400 mg in the evening.

A daily dose of 800 mg is split into two doses: 400 mg in the morning and 400 mg in the evening. A 600 mg dose can be taken as one 400 mg tablet plus two 100 mg tablets.

How to take:

  • • Take with a meal and a large glass of water to protect the stomach lining.
  • • If the tablet is hard to swallow, it can be dispersed in about 200 ml of water or apple juice, stirred with a spoon until fully dissolved and drunk immediately.
  • • Patients with liver or kidney impairment usually receive the minimum dose of 400 mg daily.
  • • Do not stop treatment or change the dose on your own: the duration of therapy is decided by your doctor.

Glivec 400 must not be used:

  • • In case of hypersensitivity to imatinib or to any of the excipients.

Use with caution (under medical supervision):

  • • in liver, kidney or heart disease, including a history of these conditions;
  • • in patients taking levothyroxine after thyroidectomy;
  • • in patients who have had hepatitis B or may have a current infection: imatinib can cause hepatitis B reactivation;
  • • during pregnancy and breastfeeding (see the pregnancy section);
  • • in children: growth may slow down, so the doctor monitors the child's growth regularly.

During treatment, blood counts, liver and kidney function and body weight (because of possible fluid retention) are monitored regularly.

Tell your doctor about all medicines you take, including over-the-counter and herbal products.

  • • CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, some antivirals, grapefruit juice) increase imatinib levels and the risk of side effects.
  • • CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, dexamethasone, St John's wort) reduce imatinib levels and may lower its efficacy.
  • • Drugs metabolized by CYP3A4 (simvastatin, ciclosporin, pimozide, some calcium channel blockers and others): imatinib may increase their levels.
  • • Warfarin and other anticoagulants: imatinib affects their action; low-molecular-weight heparins are usually preferred when anticoagulation is needed.
  • • Paracetamol: long-term combined use increases the strain on the liver.
  • • Levothyroxine: the dose may need adjustment after thyroidectomy.

Pregnancy:
Imatinib should not be used during pregnancy unless the doctor considers it clearly necessary: animal studies have shown harm to the fetus. Women of childbearing potential must use effective contraception during treatment.

Breastfeeding:
Imatinib and its active metabolite pass into breast milk. Breastfeeding must be stopped during treatment and for at least 15 days after the last dose.

Fertility:
Patients concerned about their fertility should discuss it with their doctor before starting treatment.

Driving: dizziness, drowsiness and blurred vision may occur; if so, do not drive or operate machinery.

Most side effects of imatinib are mild to moderate. The most common are:

  • • Fluid retention and edema (very common): swelling around the eyes, ankles and legs, weight gain. Rapid weight gain should be reported to the doctor.
  • • Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, indigestion.
  • • Muscles and bones: muscle spasms and cramps, muscle, joint and bone pain.
  • • Blood: decreased neutrophils, platelets and hemoglobin — blood counts are therefore checked regularly.
  • • Skin: rash, itching, dry skin, changes in skin color.
  • • General: weakness and fatigue, headache, dizziness.

Contact your doctor immediately in case of rapid weight gain, shortness of breath, chest pain, signs of bleeding, severe abdominal pain, blood in stool or vomit, yellowing of the skin, severe skin reactions or fever.

Symptoms:
Overdose intensifies the side effects: nausea, vomiting, diarrhea, rash, edema, muscle cramps, marked decrease in blood counts and raised liver enzymes.

What to do:
If you have taken more tablets than prescribed, contact a doctor immediately and take the pack with you. There is no specific antidote; treatment is symptomatic under medical supervision.

Missed dose: if you forget a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed one. Do not take a double dose.

Storage of Glivec 400:

  • 🌡️ Temperature: store at room temperature below 30 °C.
  • 💧 Moisture: store in the original package.
  • 👶 Safety: keep out of the reach of children.
  • ⏳ Expiry: shown on the carton ("Son Kullanma Tarihi"). Do not use after the expiry date.
  • 📋 Dispensing: prescription only.

To check the authenticity of Glivec 400 by Novartis (Turkish pack), look for the following:

  • ✅ Branded carton: a white box with glivec® 400 mg Film Kaplı Tablet and Imatinib, the mark 30 Film Kaplı Tablet, the NOVARTIS logo and embossed Braille on the front.
  • ✅ Turkish labeling: a 2D code (karekod) of the Turkish medicine-tracking system, a barcode, batch number (Parti No) and expiry date (Son Kullanma Tarihi) on the carton.
  • ✅ Authorization holder and manufacturer: Novartis Sağlık, Gıda ve Tarım Ürünleri San. ve Tic. A.Ş., Istanbul (manufactured in Pendik).
  • ✅ Tablets: oval, dark yellow to brownish-orange, debossed "NVR" on one side and "SL" on the other.
  • ✅ Leaflet: a Novartis patient leaflet in Turkish (Kullanma Talimatı) inside the pack.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00